<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314403</url>
  </required_header>
  <id_info>
    <org_study_id>MGH Tolerance Trial</org_study_id>
    <nct_id>NCT02314403</nct_id>
  </id_info>
  <brief_title>Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and effectiveness of a combination kidney and bone marrow&#xD;
      transplant from a haplo-identical related donor. An investigational medication and other&#xD;
      treatments will be given prior to and after the transplant to help protect the transplanted&#xD;
      kidney from being attacked by the body's immune system&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2021</completion_date>
  <primary_completion_date type="Actual">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Successful Withdrawal of Immunosuppression</measure>
    <time_frame>5 Years</time_frame>
    <description>The Primary Outcome is: The induction of transient mixed chimerism and renal allograft tolerance (24 consecutive months off of immunosuppression)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>A selective T-cell (lymphocyte) costimulation blocker</description>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>A T-Cell Depleting Agent</description>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>B-Cell Depleting Agent</description>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thymic Irradiation</intervention_name>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combined Bone Marrow/Kidney Transplantation</intervention_name>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18-60 years of age&#xD;
&#xD;
          -  Candidate for a living-donor renal allograft from an HLA mismatched donor&#xD;
&#xD;
          -  First or second transplant with either a living donor or cadaveric transplant as the&#xD;
             first transplant.&#xD;
&#xD;
          -  Use of FDA-approved methods of contraception by all recipients from the time that&#xD;
             study treatment begins until 104 weeks (24 months) after renal transplantation.&#xD;
&#xD;
          -  Ability to understand and provide informed consent.&#xD;
&#xD;
          -  Serologic evidence of prior exposure to EBV.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ABO blood group-incompatible renal allograft.&#xD;
&#xD;
          -  Evidence of anti-HLA antibody within 60 days prior to transplant as assessed by&#xD;
             routine methodology (AHG and/or ELISA)&#xD;
&#xD;
          -  Leukopenia or thrombocytopenia.&#xD;
&#xD;
          -  Positive for HIV-1, hepatitis B core antigen, or hepatitis C virus; or positivity for&#xD;
             hepatitis B surface antigen.&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 40% or clinical evidence of insufficiency.&#xD;
&#xD;
          -  Forced expiratory volume FEV1 &lt; 50% of predicted.&#xD;
&#xD;
          -  Lactation or pregnancy.&#xD;
&#xD;
          -  History of cancer other than basal cell carcinoma of the skin or carcinoma in situ of&#xD;
             the cervix.&#xD;
&#xD;
          -  Underlying renal disease etiology with a high risk of disease recurrence in the&#xD;
             transplanted kidney (such as focal segmental glomerulosclerosis, type I or II&#xD;
             membranoprolifertive glomerulonephritis).&#xD;
&#xD;
          -  Prior dose-limiting radiation therapy.&#xD;
&#xD;
          -  Known genetic disease or family history that may result in greater sensitivity to the&#xD;
             effects of irradiation, or a physical deformity that would preclude adequate shielding&#xD;
             or appropriate dosing during the irradiation component of the conditioning regimen.&#xD;
&#xD;
          -  Enrollment in other investigational drug studies within 30 days prior to enrollment.&#xD;
&#xD;
          -  Abnormal (&gt;2 times lab normal) values for (a) liver function chemistries (ALT, AST,&#xD;
             AP), (b) bilirubin, (c) coagulation studies (PT, PTT).&#xD;
&#xD;
          -  Allergy or sensitivity to any component of belatacept, ATG, tacrolimus, or rituximab.&#xD;
&#xD;
          -  Maintenance immunosuppression within 3 months prior to conditioning other than&#xD;
             physiological doses of steroids, defined as â‰¤ 50 mg of hydrocortisone or dose&#xD;
             equivalent.&#xD;
&#xD;
          -  The presence of any medical condition that the investigator deems incompatible with&#xD;
             participation in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatsuo Kawai, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21666482?dopt=Abstract</url>
    <description>Kawai T, Cosimi AB, Sachs DH. Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant. 2011 Aug;16(4):366-71.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21839648?dopt=Abstract</url>
    <description>Sachs DH, Sykes M, Kawai T, Cosimi AB. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol. 2011 Jun;23(3):165-73.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/18216355?dopt=Abstract</url>
    <description>Kawai T, (et.al.) HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008 Jan 24;358(4):353-61.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <results_first_submitted>August 6, 2021</results_first_submitted>
  <results_first_submitted_qc>August 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2021</results_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tatsuo Kawai, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Surgery, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>ESRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02314403/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combined Bone Marrow and Kidney Transplantation</title>
          <description>Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.&#xD;
Belatacept: A selective T-cell (lymphocyte) costimulation blocker&#xD;
ATG: A T-Cell Depleting Agent&#xD;
Rituximab: B-Cell Depleting Agent&#xD;
Total Body Irradiation&#xD;
Thymic Irradiation&#xD;
Combined Bone Marrow/Kidney Transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combined Bone Marrow and Kidney Transplantation</title>
          <description>Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.&#xD;
Belatacept: A selective T-cell (lymphocyte) costimulation blocker&#xD;
ATG: A T-Cell Depleting Agent&#xD;
Rituximab: B-Cell Depleting Agent&#xD;
Total Body Irradiation&#xD;
Thymic Irradiation&#xD;
Combined Bone Marrow/Kidney Transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Successful Withdrawal of Immunosuppression</title>
        <description>The Primary Outcome is: The induction of transient mixed chimerism and renal allograft tolerance (24 consecutive months off of immunosuppression)</description>
        <time_frame>5 Years</time_frame>
        <population>Two subjects underwent conditioning regimen</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Bone Marrow and Kidney Transplantation</title>
            <description>Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.&#xD;
Belatacept: A selective T-cell (lymphocyte) costimulation blocker&#xD;
ATG: A T-Cell Depleting Agent&#xD;
Rituximab: B-Cell Depleting Agent&#xD;
Total Body Irradiation&#xD;
Thymic Irradiation&#xD;
Combined Bone Marrow/Kidney Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Successful Withdrawal of Immunosuppression</title>
          <description>The Primary Outcome is: The induction of transient mixed chimerism and renal allograft tolerance (24 consecutive months off of immunosuppression)</description>
          <population>Two subjects underwent conditioning regimen</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>An adverse event is any occurrence or worsening of an undesirable or unintended sign, symptom, laboratory finding, or disease that occurs during participation in the trial.&#xD;
An adverse event will be followed until it resolves or until 30 days after a participant terminates from the study, whichever comes first.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined Bone Marrow and Kidney Transplantation</title>
          <description>Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.&#xD;
Belatacept: A selective T-cell (lymphocyte) costimulation blocker&#xD;
ATG: A T-Cell Depleting Agent&#xD;
Rituximab: B-Cell Depleting Agent&#xD;
Total Body Irradiation&#xD;
Thymic Irradiation&#xD;
Combined Bone Marrow/Kidney Transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic Microangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Heel pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HSV Lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The incidence of adverse events found around 10 days after bone marrow transplant.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tatsuo Kawai, MD PhD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-0289</phone>
      <email>tkawai@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

